Niagen Bioscience Inc (NAGE)
Healthcare
- Fundamental
- 2
- Sentiment
- 2
- Technical
- 1
Do Nothing: fundamentalScore is 2 and qualitativeScore is 2 (both below the required floor of 3), and the chart itself is a score-1 broken downtrend (price 2.095 below SMA20 2.39, SMA50 2.70 and SMA200 3.76 with MACD -0.16 < 0 and ADX 38.2); liquidity fails as well (20-day average dollar volume $1.30M and recent 3-session average $0.84M, both far under their floors). No pullback limit qualifies: a bid toward the 2.04-2.07 support shelf is countertrend under the SMA50 with MACD < 0 and is barred by every liquidity gate; no breakout stop qualifies either: a buy-stop above the 2026-11-09 settled high of 2.29 pairs with the 3-session sub-entry swingLow of 2.07 (buffer 0.03, stop 2.04) for risk 0.26 against target1 0.26, an R/R of about 1.00 that is uneconomic and below the 1.5 requirement.
Company overview
Niagen Bioscience, Inc. is a bioscience company focused on developing products for healthy aging. It operates through consumer products, ingredients, and pharmaceutical segments, offering dietary supplements and proprietary ingredient technologies. The company distributes its flagship NIAGEN products through various online platforms and retailers.
Fundamental
weakNiagen Bioscience shows weakening fundamentals with declining revenue, legal risks, and reliance on non-recurring gains.
Optically cheap with a net-cash balance sheet, but revenue is contracting (-20% year over year in Q3 2026), the operating line has swung to a loss, trailing profit is flattered by one-time gains, and legal, supplier and patent risks are unresolved - a weakening fundamental picture behind a low headline multiple.
Sentiment
weakMarket sentiment is mildly negative following a revenue miss and a target price cut by Freedom Broker.
Q3 2026 results (2026-11-04, announced) are the dominant catalyst and the market read them negatively — revenue of $27.2M against an IBES estimate near $32.1M, a $1.2M net loss and a 47% drop in ingredient sales — reinforced two days later by Freedom Broker maintaining Buy but cutting its target to $6 from $8.50; the news sentiment delta is determinate and mildly negative (baseline polarity ≈ +0.05 versus scoring ≈ -0.07) and retail is indeterminate because Reddit access was blocked. The Red-Flag Screen returned no severe flag and no moderate cap fired, but with no forward-dated catalyst in the next 30 days and no market-rewarded bullish element anywhere in the array, the post-miss digestion has nothing to offset it.
Technical
very weakThe stock is in a strong bearish trend, with price below all major moving averages and no bullish setup present.
Structurally broken downtrend, not a bullish setup. NAGE closed 2.10 on 2026-11-11 beneath every trend reference: SMA20 2.39, SMA50 2.70, SMA200 3.76, EMA9 2.25, EMA21 2.39, WMA9 2.21, WMA21 2.33 and the 2.125 daily VWAP, with the 20/50/200 stack in bearish order and all three averages still declining (SMA20 2.57 -> 2.39, SMA50 2.88 -> 2.70, SMA200 3.94 -> 3.76 over ten sessions). Momentum confirms rather than contradicts the trend: MACD -0.16 sits below its -0.14 signal and below zero, RSI14 is 35.65 (weak, not washed out), Williams %R is -89.09, and ADX14 at 38.24 is a direction-agnostic reading that, paired with price under all moving averages, describes a strong DOWN trend rather than a compression coil. The 2026-11-09 push to 2.28 failed within two sessions and printed a lower high under the 2.34 (11-05) and 2.59 (11-04) November peaks, so the bounce attempt repaired nothing. There is no positive divergence, no base, and no reclaim of any near-term average; the tape is a descending sequence of lower highs and lower lows from the May 2026 4.97 level. Score 1 (bearish/broken structure).
You’re looking at 2026-11-12 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

